Track topics on Twitter Track topics that are important to you
Novartis will partner with Cerulean Pharma to develop nanoparticle-drug conjugates (NDCs) that combine Cerulean’s proprietary Dynamic Tumor Targeting™ technology with Novartis’ proprietary compounds, to be directed at up to five undisclosed cancer targets. Cerulean said today it will generate $5 million upfront through the companies’ collaboration, plus funding for five full-time equivalent employees. Cerulean may potentially make millions more in payments tied to achieving preclinical, clinical, regulatory, and sales milestones for each target. Following regulatory approvals, Cerulean could also earn single-digit to low double-digit tiered royalties on net sales for each NDC product. Under the collaboration, Cerulean will create NDC candidates using its Dynamic Tumor Targeting platform, with Novartis agreeing to oversee further development and commercialization of those products. “This collaboration is further validation of our powerful technology platform, and we are excited that Novartis is including NDCs in its drug discovery and development efforts,” Cerulean ...NEXT ARTICLE
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...